Menatetrenone
Trade name: MK-4
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
3
Phase 4
3
Earliest trial started Apr 1, 1996 (NCT00165607)
Timeline
Indications
Approved for
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O- Mol. weight
- 444.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL259223 ↗
Also known as
- 2-methyl-3-all-trans-tetraprenyl-1,4-naphthoquinone
- 2-methyl-3-trans-tetraprenyl-1,4-naphthoquinone
- (e,e,e)-isomer of menatetrenone
- kefton-2
- menaquinone 4
- menaquinone 4
- menaquinone-4
- menatetrenone
- menatetrenone
- menatetrenone
- menatetrenone
- menatetrenone
- menatetrenone
- menatetrenone
- menatetrenone
- vitamin k2(20)
- vitamin mk 4
- vitamin mk-4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00960973 | Phase 4 | Sep 1, 2009 | Seoul National University |
| NCT00165698 | Phase 3 | May 1, 2005 | Eisai |
| NCT00165633 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2004 | Eisai |
| NCT00548509 | Phase 4 | Feb 1, 2002 | Eisai |
| NCT00062595 | Phase 3 | Sep 1, 2000 | Eisai, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT00165607 | Phase 4 | Apr 1, 1996 | Eisai |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 5 | 4 | 2 | 1996 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2000 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2009 |
3 organizations
Page 1 / 1